Antibody-drug conjugate/ADC related

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development. ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins. The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References
  1. Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33-46.
  2. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4).

ADC related products

MedChemExpress offers more than 700+ ADC related products.

Cat. No.DescriptionCASMolecular FormulaMolecular Weight
HY-2058410-Deacetyl-7-xylosyl paclitaxel90332-63-1C50H57NO17943.98
HY-789616-Maleimidohexanoic acid N-hydroxysuccinimide ester55750-63-5C14H16N2O6308.29
HY-19812Acetylene-linker-Val-Cit-PABC-MMAE 1411977-95-1C67H106N10O161307.62
HY-16261Aldoxorubicin1361644-26-9C37H42N4O13750.75
HY-W040165Amino-PEG3-C2-acid784105-33-5C9H19NO5221.25
HY-W008005Amino-PEG4-alcohol86770-74-3C8H19NO4193.24
HY-19839Ansamitocin P 3'66547-09-9C32H43ClN2O9635.14
HY-15739Ansamitocin P-366584-72-3C32H43ClN2O9635.14
HY-15582Auristatin E160800-57-7C40H69N5O7732.01
HY-15583Auristatin F163768-50-1C40H67N5O8745.99
HY-130324Azido-PEG7-amine1333154-77-0C16H34N4O7394.46
HY-42146BMPS55750-62-4C11H10N2O6266.21
HY-P1449Boc-Gly-Gly-Phe-Gly-OH187794-49-6C20H28N4O7436.46
HY-W011561Boc-NH-C6-Br142356-33-0C11H22BrNO2280.20
HY-W038702Boc-Val-Cit-OH870487-08-4C16H30N4O6374.43
HY-19609Calicheamicin108212-75-5C55H74IN3O21S41368.35
HY-16560Camptothecin7689-03-4C20H16N2O4348.35
HY-128946CL2A-SN-381279680-68-0C73H97N11O221480.61
HY-126517Cyclooctyne-O-NHS ester1425803-45-7C14H17NO5279.29
HY-126518Cyclooctyne-O-PFP ester886209-60-5C16H13F5O3348.26
HY-15750Cys-mcMMADC54H84N8O11S21085.42
HY-15581SD8-MMADC41H58D8N6O6S779.11
HY-15162AD8-MMAE2070009-72-0C39H59D8N5O7726.03
HY-15579ASD8-MMAF hydrochlorideC39H58D8ClN5O8776.47
HY-13061Daun02290304-24-4C41H44N2O20884.79
HY-13062Daunorubicin hydrochloride23541-50-6C27H30ClNO10563.98
HY-111012DBCO-(PEG)3-VC-PAB-MMAEC86H124N12O181613.97
HY-42972DBCO-acid1353016-70-2C19H15NO3305.33
HY-42973DBCO-NHS ester1353016-71-3C23H18N2O5402.40
HY-133431DBCO-PEG3-SS-NHS esterC34H39N3O9S2697.82
HY-129379DC0-NH2615538-51-7C31H24ClN5O3550.01
HY-112898DC1SMe501666-85-9C35H30ClN5O4S2684.23
HY-13631EDeruxtecan1599440-13-7C52H56FN9O131034.05
HY-130080DM3796073-54-6C37H52ClN3O10S766.34
HY-130082DM4-SMe796073-68-2C39H56ClN3O10S2826.46
HY-15580Dolastatin 10110417-88-4C42H68N6O6S785.09
HY-15142Doxorubicin hydrochloride25316-40-9C27H30ClNO11579.98
HY-125331DRF-1042200619-13-2C22H20N2O6408.40
HY-114697DSG Crosslinker79642-50-5C13H14N2O8326.26
HY-118759DSP Crosslinker57757-57-0C14H16N2O8S2404.42
HY-W019543DSS Crosslinker68528-80-3C16H20N2O8368.34
HY-18987Duocarmycin MA1613286-57-9C34H31ClN4O5611.09
HY-107769Duocarmycin TM157922-77-5C25H23ClN2O5466.91
HY-13631DDxd1599440-33-1C26H24FN3O6493.48
HY-W007713Fmoc-8-amino-3,6-dioxaoctanoic acid166108-71-0C21H23NO6385.41
HY-W040238Fmoc-NH-PEG2-CH2CH2COOH872679-70-4C22H25NO6399.44
HY-19318Fmoc-Val-Cit-PAB159858-22-7C33H39N5O6601.69
HY-126532Fmoc-Val-Cit-PAB-Duocarmycin TMC58H60ClN7O101050.59
HY-19811Fmoc-Val-Cit-PAB-MMAE1350456-56-2C73H104N10O141345.67
HY-41189Fmoc-Val-Cit-PAB-PNP863971-53-3C40H42N6O10766.80
HY-130812Gemcitabine-O-Si(di-iso)-O-McC24H36F2N4O7Si558.65
HY-W067061Hydroxy-PEG2-(CH2)2-Boc133803-81-3C11H22O5234.29
HY-42488Hydroxy-PEG3-(CH2)2-Boc186020-66-6C13H26O6278.34
HY-W039178Hydroxy-PEG4-(CH2)2-Boc518044-32-1C15H30O7322.39
HY-101982Lys-SMCC-DM11281816-04-3C53H75ClN6O15S1103.71
HY-44222MAC glucuronide linker-2229977-57-5C20H25NO11455.41
HY-128943MAC glucuronide phenol-linked SN-382246380-69-6C50H54N6O20S1091.06
HY-101159Mal-amido-PEG8-C2-acid1334177-86-4C26H44N2O13592.63
HY-100567MAL-di-EG-Val-Cit-PAB-MMAEC72H112N12O181433.73
HY-128711MAL-di-EG-Val-Cit-PAB-MMAFC73H113N13O191476.75
HY-133540Maleimide-DOTA1006711-90-5C22H34N6O9526.54
HY-128870Mal-PEG2-VCP-Eribulin2130869-18-8C70H99N7O211374.57
HY-130084Mal-PEG2-VCP-NB2395887-69-9C36H45N7O13783.78
HY-19474Maytansinol57103-68-1C28H37ClN2O8565.06
HY-136286MC-DM1 1375089-56-7C42H55ClN4O12843.36
HY-114233MC-GGFG-DX89511600418-29-8C49H51FN8O11946.97
HY-15740Mc-MMAD1401963-15-2C51H77N7O9S964.26
HY-15741Mc-MMAE863971-24-8C49H78N6O10911.18
HY-15578McMMAF863971-19-1C49H76N6O11925.16
HY-78738MC-Val-Cit-PAB159857-80-4C28H40N6O7572.65
HY-20336Mc-Val-Cit-PABC-PNP159857-81-5C35H43N7O11737.76
HY-112786MC-Val-Cit-PAB-MMAF863971-17-9C68H103N11O161330.61
HY-128955MC-VC-PABC-Aur01011438849-92-3C68H100N12O14S1341.66
HY-131057Mc-VC-PAB-SN381801838-28-7C51H58N8O13991.05
HY-19792Mertansine139504-50-0C35H48ClN3O10S738.29
HY-14519Methotrexate59-05-2C20H22N8O5454.44
HY-15581MMAD203849-91-6C41H66N6O6S771.06
HY-15579AMMAF hydrochloride1415246-68-2C39H66ClN5O8768.42
HY-15579BMMAF sodium1799706-65-2C39H64N5NaO8753.94
HY-79256MMAF-OMe863971-12-4C40H67N5O8745.99
HY-15162Monomethyl auristatin E474645-27-7C39H67N5O7717.98
HY-W018174m-PEG3-Amine74654-07-2C7H17NO3163.21
HY-100874N3-PEG3-vc-PAB-MMAEC67H109N13O161352.66
HY-W002213N-Hydroxysulfosuccinimide sodium106627-54-7C4H4NNaO6S217.13
HY-112100PAC2158322-33-7C94H107N13O161674.93
HY-B0015Paclitaxel33069-62-4C47H51NO14853.91
HY-126498PDEC-NB874302-76-8C14H12N2O5S2352.39
HY-128968PEG4-aminooxy-MMAF1415246-35-3C47H82N6O12923.19
HY-12522PF-063801011436391-86-4C39H62N6O6S743.01
HY-129362Phe-Lys(Fmoc)-PAB2149584-03-0C37H40N4O5620.74
HY-114936Piericidin A2738-64-9C25H37NO4415.57
HY-16700PNU-159682202350-68-3C32H35NO13641.62
HY-126511Propargyl-C1-NHS ester132178-37-1C9H9NO4195.17
HY-129938PROTAC BRD4 degrader for PAC-1C62H77F2N9O12S41306.58
HY-19829Sandramycin100940-65-6C60H76N12O161221.32
HY-126681SC-VC-PAB-MMAE2259318-46-0C68H105N11O171348.62
HY-129356Seco-Duocarmycin SA144667-38-9C25H24ClN3O7513.93
HY-130083Seco-Duocarmycin TM236102-87-7C25H24N2O6448.47
HY-101162SGD-19101342820-51-2C60H64N8O121089.20
HY-14573SJG-136232931-57-6C31H32N4O6556.61
HY-42360SMCC64987-85-5C16H18N2O6334.32
HY-101070SMCC-DM11228105-51-8C51H66ClN5O16S1072.61
HY-13704SN-3886639-52-3C22H20N2O5392.40
HY-104025SPB858128-57-1C19H15NO8385.32
HY-12448SPDB115088-06-7C13H14N2O4S2326.39
HY-12460SPDB-DM41626359-62-3C46H63ClN4O14S2995.59
HY-100216SPDP68181-17-9C12H12N2O4S2312.36
HY-79369Succinic anhydride108-30-5C4H4O3100.07
HY-D0975Sulfo-SMCC sodium92921-24-9C16H17N2NaO9S436.36894928
HY-101151sulfo-SPDB1193111-39-5C13H14N2O7S3406.45
HY-101141sulfo-SPDB-DM41626359-59-8C46H63ClN4O17S31075.66
HY-100566SuO-Val-Cit-PAB-MMAEC63H97N11O161264.51
HY-15584Taltobulin228266-40-8C27H43N3O4473.65
HY-15584BTaltobulin hydrochlorideC27H44ClN3O4510.11
HY-15584ATaltobulin trifluoroacetate228266-41-9C29H44F3N3O6587.67
HY-100374Val-Cit-PAB-MMAE644981-35-1C58H94N10O121123.43
HY-12362Val-cit-PAB-OH159857-79-1C18H29N5O4379.45
HY-126492Vat-Cit-PAB-Monomethyl Dolastatin 101415329-13-3C60H93N11O11S1176.51
HY-15742Vc-MMAD 1401963-17-4C70H104N12O14S1369.71
HY-15575VcMMAE646502-53-6C68H105N11O151316.63
HY-117410Vipivotide tetraxetan1702967-37-0C49H71N9O161042.14
HY-43869Vipivotide tetraxetan Linker1703768-74-4C33H45N5O9655.74

More products can be found in our search engine.